Current Concept and Emerging Treatments of Coronary Artery Disease (CAD)

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 384

Special Issue Editors


E-Mail Website
Guest Editor
Division of Cardiology, Cardio-Thoracic Department, University of Verona, 37100 Verona, Italy
Interests: coronary physiology; intracoronary imaging; imaging-derived computational physiology; drug coated balloon and bioresorbable scaffolds; virtual PCI; artificial-intelligence

E-Mail
Guest Editor
Department of Cardiology, University of Verona, 37129 Verona, Italy
Interests: coronary physiology; intracoronary imaging; imaging-derived computational physiology; drug coated balloon and bioresorbable scaffolds; virtual PCI; artificial-intelligence

Special Issue Information

Dear Colleagues,

Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide, necessitating continual advancements in its diagnosis, treatment, and management. The understanding of CAD progression has expanded, including the role of inflammation, endothelial dysfunction, and plaque instability as critical factors in disease progression, leading to new therapeutic targets.

This Special Issue will dive deep into the current state of PCI, emphasizing the ongoing debate around the appropriateness of stent-based revascularization. Reliance on angiography alone can lead to inappropriate treatment decisions, while physiological assessments are crucial for ensuring that PCI is both appropriate and effective.

Secondly, this Special Issue will focus on the concept of residual angina post-PCI, exploring how suboptimal revascularization and/or microvascular dysfunction contribute to ongoing patient symptoms.

Third, this Special Issue will focus on the emerging role of simulated virtual PCI and advanced imaging-derived technologies that integrate anatomical and physiological data for better procedural planning and outcomes.

Lastly, new emerging technologies, such as drug-coated balloons and bioresorbable stents, are gaining attention as alternatives to traditional drug-eluting stents. These technologies aim to reduce long-term complications associated with permanent implants, such as late stent thrombosis and restenosis.

This Special Issue highlights the need for ongoing research and collaboration among clinicians, researchers, and industry to further refine and implement these emerging treatments, ultimately improving outcomes for patients with coronary artery disease.

Dr. Simone Fezzi
Dr. Roberto Scarsini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • coronary physiology
  • intracoronary imaging
  • imaging-derived computational physiology
  • drug-coated balloon and bioresorbable scaffolds
  • virtual PCI
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 586 KiB  
Article
Pantera Lux Drug-Coated Balloon for the Treatment of Coronary Artery Lesions in Routine Practice
by Rayyan Hemetsberger, Nader Mankerious, Kevin Hamzaraj, Ahmed Alali, Gert Richardt and Ralph Tölg
J. Clin. Med. 2025, 14(9), 3133; https://doi.org/10.3390/jcm14093133 - 1 May 2025
Viewed by 114
Abstract
Background/Objectives: We sought to confirm the performance and safety of the Pantera Lux paclitaxel-coated balloon (pDCB) when used as per the instructions for use at a single high-volume center. Methods: In this retrospective analysis, 386 consecutive patients were categorized into three groups: the [...] Read more.
Background/Objectives: We sought to confirm the performance and safety of the Pantera Lux paclitaxel-coated balloon (pDCB) when used as per the instructions for use at a single high-volume center. Methods: In this retrospective analysis, 386 consecutive patients were categorized into three groups: the treatment of drug-eluting stent in-stent restenosis (DES-ISR) lesions (n = 191), bare-metal stent in-stent restenosis (BMS-ISR) lesions (n = 127), and de novo lesions (n = 68). The primary endpoint at 12 months was target-lesion revascularization (TLR). Secondary endpoints were device success, target-vessel myocardial infarction (TV-MI), and cardiac death. Results: The baseline characteristics were balanced between the groups, with a median age of 71.3 years, 25% being female, 32% being diabetic. The majority presented with chronic coronary syndrome (82.9%). Type C lesions were more often observed in the DES-IRS group as compared with the BMS-IRS and de novo groups (15.6% vs. 7.9% vs. 7.4%, p < 0.001). Cutting balloons were more often used in the DES-IRS group (41.0% vs. 19.7% vs. 1.5%, p < 0.001). The residual stenosis rate was 7.6% vs. 3.3% vs. 7.3% (p = 0.002). The TLR at 12 months was 8.9% vs. 2.4% vs. 1.5% (p = 0.013). Device success was achieved in 98.8% vs. 98.5% vs. 100% of cases (p = 0.8). TV-MI occurred in 3.2% vs. 0.8% vs. 1.5% (p = 0.5) and cardiac death in 2.6% vs. 0.0% vs. 2.9% (p = 0.13) in DES-IRS vs. BMS-IRS vs. de novo lesions. Conclusions: In this single-center observation, we confirmed the safety and efficacy of the Pantera Lux paclitaxel-coated balloon for the treatment of DES-IRS, BMS-IRS, and de novo lesions with low TLR rates at 12 months. Full article
Show Figures

Figure 1

Back to TopTop